Convergen announced the closing of a USD 10 million seed financing round. The round was invested by Qiming Venture Partners, a global venture capital firm focused on life sciences and healthcare innovation.

Funds from the financing will accelerate the development of Convergen's proprietary TrimTAC platform—next-generation bifunctional degraders leveraging the E3 ubiquitin ligase TRIM21—and advance its early pipeline of therapies for neurodegenerative disorders and diseases with massive unmet medical needs.

Despite their transformative potential, traditional bifunctional degraders face two major hurdles: overreliance on a limited set of E3 ligases and, crucially, inability to selectively eliminate pathogenic multimeric protein aggregates—the root cause of many neurodegenerative diseases.

Speaking on the funding, Dr Jinquan Sun, Co-Founder, Convergen, said, "The seed financing—led by Qiming Venture Partners—validates TrimTAC's potential to redefine treatment for diseases caused by pathogenic multimeric proteins. Together with Qiming, we will expand our expertise in TPD and CNS drug development, accelerate our pipeline toward clinical proof-of-concept, and deliver on our mission to help patients with limited treatment options."

Dr Ting Han, Scientific Co-Founder, Convergen and Associate Investigator, NIBS, Beijing, is a protein degradation expert whose pivotal work in the field includes elucidation of the mechanism of action of RBM39 degraders (Science 2017) and the recent discovery of TRIM21-based molecular glue degraders (Cell 2024, ACS Chemical Biology 2025).

Dr Kan Chen, Partner and Co-Lead—Healthcare, Qiming Venture Partners, said, "Convergen's TrimTAC platform addresses a critical gap in TPD—selective degradation of multimeric aggregates—that has held back progress in neurodegenerative diseases. The company's world-class scientific foundation, combined with its veteran leadership team, positions it to become a leader in advancing the next-generation protein degradation. We are proud to partner with Convergen and support its journey to bring transformative therapies to patients."